Camurus Logo

Camurus

Develops long-acting medicines for severe chronic diseases using advanced drug delivery.

CAMX | ST

Overview

Corporate Details

ISIN(s):
SE0007692850 (+2 more)
LEI:
5493003S6Z6VI7WYFQ06
Country:
Sweden
Address:
Ideon Science Park, 223 70 Lund
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Camurus is a science-led international biopharmaceutical company focused on developing and commercializing innovative, long-acting medicines for severe and chronic diseases. Leveraging its expertise in advanced drug delivery systems, the company aims to improve treatment outcomes and quality of life for patients. Camurus' development pipeline and commercial products target significant unmet medical needs in therapeutic areas including diseases of the central nervous system, rare diseases, endocrinology, oncology, and supportive care.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-30 07:00
Declaration of Voting Results & Voting Rights Announcements
Förändring av antalet aktier och röster i Camurus
Swedish 134.6 KB
2025-09-30 07:00
Declaration of Voting Results & Voting Rights Announcements
Change in number of shares and votes in Camurus
English 136.1 KB
2025-07-17 07:00
Earnings Release
Swedish 923.9 KB
2025-07-17 07:00
Quarterly Report
English 916.2 KB
2025-07-01 11:30
Regulatory News Service
Camurus’ Oczyesa® receives marketing authorization for treatment of acromegaly …
English 184.9 KB
2025-07-01 11:30
Earnings Release
Camurus meddelar EU-godkännande av Oczyesa® för behandling av akromegali
Swedish 182.4 KB
2025-06-30 07:00
Declaration of Voting Results & Voting Rights Announcements
Förändring av antalet aktier och röster i Camurus
Swedish 130.6 KB
2025-06-30 07:00
Declaration of Voting Results & Voting Rights Announcements
Change in number of shares and votes in Camurus
English 141.7 KB
2025-06-18 08:00
Regulatory News Service
Camurus’ POSITANO study shows treatment effects with CAM2029 in polycystic live…
English 168.7 KB
2025-06-18 08:00
Regulatory News Service
Camurus studie POSITANO visar behandlingseffekt av CAM2029 i patienter med poly…
Swedish 167.8 KB
2025-06-03 19:45
M&A Activity
Camurus and Lilly ingår samarbets- och licensavtal avseende långtidsverkande in…
Swedish 169.9 KB
2025-06-03 19:45
Regulatory News Service
Camurus and Lilly enter collaboration and license agreement for long-acting Flu…
English 171.3 KB
2025-05-27 21:30
Transaction in Own Shares
Camurus styrelse utnyttjar återköpsbemyndigande för säkerställande av bolagets …
Swedish 135.3 KB
2025-05-27 21:30
Share Issue/Capital Change
Camurus’ Board of Directors exercises authorization for repurchase of shares fo…
English 141.2 KB
2025-05-27 18:50
Post-Annual General Meeting Information
Resolutions at the annual general meeting 2025 in Camurus
English 155.3 KB

Automate Your Workflow. Get a real-time feed of all Camurus filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Camurus via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-07-17 Torsten Malmström Other Sell 10,000 6,806,400.00 SEK
2024-06-17 Jon Uguzne Garay Alonso Other Other 33,750 N/A
2024-05-14 Torsten Malmström Other Sell 1,495 844,675.00 SEK
2024-05-10 Annette Mattsson Other Sell 1,000 550,000.00 SEK
2023-12-15 Annette Mattsson Other Other 1,000 169,500.00 SEK
2023-09-18 Annette Mattsson Other Sell 1,000 294,600.00 SEK
2023-09-06 Maria Lundqvist Other Other 381 N/A
2023-08-23 Maria Lundqvist Other Sell 77 22,610.28 SEK
2023-08-23 Maria Lundqvist Other Sell 58 17,032.86 SEK
2023-08-23 Maria Lundqvist Other Other 77 13,051.50 SEK

Peer Companies

Company Country Ticker View
AnGes, Inc. Logo
Develops gene-based medicines like HGF gene therapy, DNA vaccines, and NF-kB decoys.
Japan 4563
ANIMALCARE GROUP PLC Logo
Develops & sells veterinary prescription & OTC medicines for professionals worldwide.
United Kingdom ANCR
Annexin Pharmaceuticals AB Logo
Developing Annexin A5 protein to treat vascular, inflammatory, and cancerous diseases.
Sweden ANNX
ANTEROGEN CO., LTD. Logo
Develops and commercializes adult stem cell therapies and orphan drugs for medical conditions.
South Korea 065660
Antibiotice S.A. Logo
Develops and manufactures generic medicines and APIs, specializing in anti-infectives.
Romania ATB
Apontis Pharma AG Logo
German pharma firm specializing in Single Pills for cardiovascular and chronic diseases.
Germany APPH
AprilBio Co.,Ltd. Logo
Develops long-acting biologic drugs for autoimmune diseases and oncology using its SAFA™ platform.
South Korea 397030
Aprogen Biologics Inc. Logo
Develops and manufactures novel biologic drugs and biosimilars for the professional market.
South Korea 003060
Aprogen, Inc Logo
Develops and manufactures novel biologics and biosimilars for cancer and arthritis treatments.
South Korea 007460
Develops drugs for fibrosis, inflammation, and cancer using NOX inhibitor & CAF modulation tech.
South Korea 293780

Talk to a Data Expert

Have a question? We'll get back to you promptly.